SMYD2 and breast carcinoma: As reported, SMYD2 promotes the stability of EZH2 in breast cancer cells and does not affect the transcription of EZH2 [10], Based on the aforementioned information, we studied the role of SMYD2 inhibitors LLY-507 and AZ-505 in the transcription and translation of EZH2 in GIST-T1 cells.